SciTech Announces Equity Crowdfunding Campaign
(GROSSE POINTE FARMS, MI) March 15, 2022 – SciTech Development LLC, a specialty pharmaceutical company, is pleased to announce the launch of its equity crowdfunding campaign on StartEngine. SciTech plans to grow the company, scale-up clinical drug manufacturing, and to commence the company's first clinical trial of ST-001 nanoFenretinide for the treatment of non-Hodgkin’s lymphoma (NHL). Non-Hodgkin’s lymphomas are cancers that begin in the lymphatic system, which is part of the body's germ-fighting immune system.
SciTech’s patented lead drug candidate ST-001 nanoFenretinide is a combination of the company’s proprietary drug delivery platform known as SDP, and fenretinide, a drug with a well-documented safety profile. SciTech is further pleased to announce that ST-001 has an FDA approved Investigational New Drug Application (IND) and Orphan Drug Designation (ODD) for two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). ST-001 is ready to enter the clinic at Rush University Medical Center (RUMC) in Chicago, IL where it has IRB approval (Institutional Review Board).
Earle Holsapple, President of SciTech Development, relays that FDA approval of ST-001 would be a significant step towards revenue generation, but more importantly, believes that SciTech's scientific breakthroughs will have a profound impact on patients who are battling cancer.
Visit https://www.startengine.com/scitechdevelopment to invest in SciTech’s crowdfunding campaign, early investors qualify for time-based bonuses. For company, product, and investor information visit www.SciTechSDP.com. Detailed information regarding SciTech’s science and the company can be found at www.SciTechDevelopment.com.
The SciTech Story
SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer treatments. We have developed a powerful, new Drug Delivery Platform (SDP) that will revolutionize how safe and promising, yet challenged drugs, can be delivered to kill cancer. SciTech has developed its first, patented drug candidate, ST-001-nanoFenretinide that combines SDP and the drug fenretinide as a broadly applicable anticancer drug. SciTech’s innovations will impact our mission to develop cost-effective therapeutics that deliver transformative clinical outcomes. SciTech Development is in the pre-revenue clinical stage of development.
Watch the video below to learn more about our story.
SDP and ST-001
Our patented lead drug candidate, ST-001 nanoFenretinide uses the SciTech Drug Delivery Platform (SDP) in combination with fenretinide, a drug with a well-documented safety profile.
Watch the video below to see how ST-001 it works.*
*The above video contains computer generated demonstrations of the SciTech Drug Delivery Platform
SciTech's Equity Crowdfunding Campaign Successful, Now Closed